An apolipoprotein(a) peptide delays chylomicron remnant clearance and increases plasma remnant lipoproteins and atherosclerosis in vivo.
OBJECTIVE
Humans with high expression of apolipoprotein(a) [apo(a)] and high plasma levels of lipoprotein(a) [Lp(a)] are at increased risk for atherosclerosis, but the mechanism is not known. We have previously shown that the KIV(5-8) domain of apo(a) has unique cell-surface binding properties, and naturally occurring fragments of apo(a) encompassing this domain are thought to be atherogenic in humans. To investigate the effect of KIV(5-8) on lipoprotein metabolism and atherosclerosis in vivo, we created several independent lines of liver-targeted KIV(5-8) transgenic mice.


RESULTS
The transgenic mice have plasma apo(a) peptide concentrations that are similar to Lp(a) concentrations in humans at risk for coronary artery disease. Remarkably, the transgenic mice had a 2- to 4-fold increase in cholesterol-rich remnant lipoproteins (RLPs) when fed a cholesterol-rich diet, and a 5- to 20-fold increase in atherosclerosis lesion area in the aortic root. Using an in vivo clearance study, we found only slight differences in the triglyceride and apolipoprotein B secretion rates between the 2 groups of mice, suggesting an RLP clearance defect. Using an isolated perfused mouse liver system, we showed that transgenic livers had a slower rate of RLP removal, which was retarded further when KIV(5-8), full-length apo(a), or Lp(a) were added to the perfusate. An apo(a) peptide that does not interact with cells, K(IV2)3, did not retard RLP removal, and low-density lipoprotein (LDL) had a much smaller effect than Lp(a).


CONCLUSIONS
We propose that high levels of apo(a)/Lp(a), perhaps acting via a specific cell-surface binding domain, inhibit hepatic clearance of remnants, leading to high plasma levels of RLPs and markedly enhanced atherosclerosis. We speculate that the KIV(5-8) region of apo(a) competes with one or more receptors for remnant clearance in the liver and that this process may represent one mechanism accounting for increased atherosclerosis in humans with high secretion levels of apo(a).
Devlin
Cecilia M
CM
Department of Medicine, Columbia University, 630 W 168th St, New York, NY 10032, USA.
Lee
Sung-Joon
SJ
Kuriakose
George
G
Spencer
Craig
C
Becker
Lev
L
Grosskopf
Itamar
I
Ko
Carol
C
Huang
Li-Shin
LS
Koschinsky
Marlys L
ML
Cooper
Allen D
AD
Tabas
Ira
I
D000818:Animals; D001011:Aorta / Q000378:metabolism / Q000473:pathology; D053299:Apolipoprotein B-100; D053283:Apolipoprotein B-48; D001054:Apolipoproteins A / Q000097:blood* / Q000235:genetics* / Q000494:pharmacology; D001055:Apolipoproteins B / Q000097:blood / Q000378:metabolism; D050197:Atherosclerosis / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D002784:Cholesterol / Q000378:metabolism*; D015243:Cholesterol, VLDL / Q000097:blood; D053298:Chylomicron Remnants; D002914:Chylomicrons / Q000097:blood*; D005260:Female; D006801:Humans; D018082:Kringles / Q000235:genetics; D008074:Lipoproteins / Q000378:metabolism*; D008099:Liver / Q000378:metabolism; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D008822:Mice, Transgenic; D051381:Rats; D014280:Triglycerides / Q000097:blood / Q000378:metabolism*
D053299:Apolipoprotein B-100; D053283:Apolipoprotein B-48; D001054:Apolipoproteins A; D001055:Apolipoproteins B; D015243:Cholesterol, VLDL; D053298:Chylomicron Remnants; D002914:Chylomicrons; D008074:Lipoproteins; D014280:Triglycerides; C112017:remnant-like particle cholesterol; D002784:Cholesterol